442 Littlefield Avenue
South San Francisco
About Blade Therapeutics
Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Blade’s novel target biology was discovered by its founder, Hal Dietz, M.D., Victor A. McKusick Professor of Genetics and Medicine, Johns Hopkins University. Blade licensed intellectual property associated with Dr. Dietz’s work and is advancing new compounds to halt the progression of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. By targeting novel pathways common to multiple fibrotic disease states, we believe we can build the leading company in anti-fibrotic drug discovery and development.
CEO: Wendye Robbins, M.D.
Please click here for Blade Therapeutics job opportunities.
43 articles about Blade Therapeutics
Blade Therapeutics, Inc. (Blade) today announced with profound sadness the unexpected passing of company General Counsel and Secretary Alan C. Mendelson on October 8, 2021, in San Francisco.
Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease
Blade Therapeutics, Inc. today announced peer-reviewed publication of preclinical study data supporting the neuroprotective effects of inhibiting dimeric calpains in spinocerebellar ataxia type-3 (SCA3).
Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)
Blade Therapeutics, Inc. today announced positive preliminary data from a new preclinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF.
Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)
Blade Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has activated the Company’s Investigational New Drug (IND) application to investigate cudetaxestat in IPF.
Blade Therapeutics, Inc., a biopharmaceutical company committed to revolutionizing the treatment of fibrotic diseases, announced the appointment of Jean-Frédéric Viret, Ph.D., as Chief Financial Officer effective immediately.
Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference.
Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the 2020 Stifel Virtual Healthcare Conference. The virtual session will take place on Monday, November 16, 2020, at 3:20 – 3:50 p.m. Eastern Time. A link to the live and archived webcast presentation can be accessed on the “News & Events” page of the Blade company website at https://www.bla
Blade Therapeutics Reaches Enrollment Goal for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients With COVID-19 Pneumonia
BLADE-CONQUER trial reached 120-subject enrollment goal Independent Data Monitoring Committee also recommended continuation of trial after planned review of blinded safety data Company expects topline results in 4Q-2020 SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Blade Therapeutics today announced that it has reached the 120-subject enrollment goal for the Phase 2 clinical study of the Company’s investigational therapeutic, BL
Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia
Blade Therapeutics today announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients. Started in May 2020
Blade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the Board
Blade Therapeutics, a leader in the fields of fibrosis, COVID-19 pathogenesis and inflammatory biology, today announced the appointment of Mark Timney as Chairman of the Board of Directors. Mr. Timney succeeds Luke Evnin, Ph.D., co-founder and Managing Director of MPM, who has served as Chairman since the founding of Blade Therapeutics in 2015. Dr. Evnin will remain a member the Board of Directors, which will
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 1:50 p.m. Eastern Time.
Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409)
Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor for patients with fibrotic diseases.
Wendye Robbins, M.D., President and Chief Executive Officer, will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 2:30 p.m. Eastern Time.
Blade Therapeutics Announces Publication of Preclinical Data Supporting Calpain 9 as a Promising Therapeutic Target for Fibrotic Disease
Findings validate the mechanism of action for the Company’s lead asset, BLD-2660
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
Blade Therapeutics Announces Initiation of Phase 1 Study of Lead Calpain Inhibitor BLD-2660 for Fibrosis
This study is being conducted in Australia with initial results from healthy volunteers expected by the fourth quarter of 2018.
Blade Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
Blade Therapeutics Announces Selection Of A Clinical Development Candidate And Funding Of The Second Tranche For Its Series B Financing
Blade Therapeutics announced that it has nominated a clinical development candidate for its lead program focused on small molecule inhibitors that selectively target certain intracellular cysteine proteases.
Blade Therapeutics Announces Appointment Of Dr. Maria E. Fuentes As Executive Vice President, Research